1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics in the United States, August 2018 (p7)

Healthcare Analysis & Statistics in the United States, August 2018 (p7)

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence

All regions

data types

181-210 of about 300 reports

Xalkori

Xalkori

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewXalkori (crizotinib; Pfizer/Merck KGaA) is a selective, adenosine triphosphate-competitive small molecule multi-kinase inhibitor of mesenchymal epithelial transition growth factor (c-Met o ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Zykadia

Zykadia

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewZykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK). In most ALK-positive non-small cell lung cancer (NSCLC) cases, inversions in chromosome ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Alecensa

Alecensa

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewAlecensa (alectinib) is a second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Roche and Chugai. In some non-small cell lung cancer (NSCLC) patients, abnormal ALK configuration ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Alimta

Alimta

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewAlimta (pemetrexed; Eli Lilly) is an antifolate antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. Similar to fluorouracil, ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Ensartinib

Ensartinib

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewEnsartinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Xcovery. In approximately 3–5% of all non-small cell lung cancer (NSCLC) patients, abnormal ALK ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Alunbrig

Alunbrig

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewAlunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. In preclinical studies, Alunbrig showed potent activity against ...

  • Industries : Cancer, Therapy, Pathology, Oncology
  • Countries : United States, Japan, European Union
Capmatinib

Capmatinib

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewCapmatinib (Incyte/Novartis) is an orally bioavailable inhibitor of the proto-oncogene c-MET, also called hepatocyte growth factor receptor (HGFR). C-MET is a receptor tyrosine kinase, and ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Portrazza

Portrazza

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewPortrazza (necitumumab; Eli Lilly) is a recombinant IgG1 monoclonal antibody (MAb) that blocks the binding of epidermal growth factor receptor (EGFR) to its ligands. This binding prevents ...

  • Industries : Therapy, Medical Biotechnology, Oncology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Renal Cell Cancer Pricing, Reimbursement, and Access

Renal Cell Cancer Pricing, Reimbursement, and Access

  • $ 2995
  • Industry report
  • August 2018

OverviewThere is moderate concern among payers regarding spend on renal cell cancer (RCC) drugs, but access restrictions remain mild. Spend in RCC is among the top five oncology indications. Although payers ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Rheumatoid Arthritis Market and Forecast Analysis to 2025

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • $ 22000
  • Industry report
  • August 2018

DISEASE OVERVIEWRheumatoid arthritis (RA) is a chronic inflammatory disease that leads to progressive joint deformity, disability, and occasionally premature death. RA may affect many tissues and organs, ...

  • Industries : Chronic Disease, Pathology
  • Countries : United States, European Union, Japan
Ninlaro

Ninlaro

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewNinlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways. Preclinical studies ...

  • Industries : Cancer
  • Countries : United States, Japan, European Union
Ygalo

Ygalo

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewYgalo (melphalan-flufenamide; Oncopeptides) is a cytotoxic alkylating agent that consists of melphalan conjugated to phenylalanine. By utilizing peptidases that are overexpressed in malignant ...

  • Industries : Cancer
  • Countries : United States, European Union
Velcade

Velcade

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewVelcade (bortezomib; Takeda/Johnson and Johnson) is an intravenously or subcutaneously administered 26S proteasome inhibitor that affects multiple signaling cascades and induces cell death. ...

  • Industries : Cancer, Therapy, Pathology
  • Countries : United States, Japan, European Union
Darzalex

Darzalex

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewDarzalex (daratumumab; Johnson and Johnson) targets the transmembrane glycoprotein CD38, which is highly expressed on malignant multiple myeloma cells, but expressed at low levels in othe ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Kyprolis

Kyprolis

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewKyprolis (carfilzomib; Amgen/Ono Pharmaceutical) is a second-generation proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Idiopathic Pulmonary Fibrosis Forecast and Market Analysis for 2035, Pharma Intelligence

Idiopathic Pulmonary Fibrosis Forecast and Market Analysis for 2035, Pharma Intelligence

  • $ 22000
  • Industry report
  • August 2018

Disease OverviewIdiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease in which scarring and thickening of the lung tissue occurs due to unknown causes. In turn, this fibrosis reduces ...

  • Industries : Healthcare
  • Countries : United States, Japan, European Union
Upadacitinib

Upadacitinib

  • $ 10000
  • Industry report
  • August 2018

DRUG OVERVIEWUpadacitinib (AbbVie) is an oral small molecule inhibitor of Janus kinase (JAK)-1 that is being developed in several indications including Crohn’s disease, rheumatoid arthritis, psoriatic ...

  • Industries : Pathology, Medical Biotechnology
  • Countries : United States, Japan, European Union
Etrolizumab

Etrolizumab

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewEtrolizumab (Roche) is a humanized anti-beta7 integrin subunit monoclonal antibody. The drug was discovered by Genentech, which was acquired by Roche in 2009. Etrolizumab binds to the beta7 ...

  • Industries : Pathology
  • Countries : United States, European Union
Crohn’s Disease Forecast and Market Analysis to 2026

Crohn’s Disease Forecast and Market Analysis to 2026

  • $ 22000
  • Industry report
  • August 2018

Disease OverviewCrohn’s disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of ...

  • Industries : Pathology
  • Countries : United States, European Union, Japan
Humira

Humira

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewHumira (adalimumab; AbbVie/Eisai) is a recombinant human immunoglobulin G1 monoclonal antibody that acts as a tumor necrosis factor (TNF) inhibitor. In the US and EU, Humira is marketed by ...

  • Industries : Pathology
  • Countries : United States, Japan, European Union
Remicade

Remicade

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewRemicade (infliximab; Johnson and Johnson/Merck and Co/Mitsubishi Tanabe) is a chimeric, humanized monoclonal antibody targeting tumor necrosis factor (TNF)-alpha, with a long history of use ...

  • Industries : Pathology
  • Countries : Japan, United States, European Union
Stelara

Stelara

  • $ 10000
  • Industry report
  • August 2018

DRUG OVERVIEWStelara (ustekinumab; Johnson and Johnson/Mitsubishi Tanabe) is a high-affinity, fully human monoclonal antibody that targets the p40 subunit of cytokines interleukin (IL)-12 and IL-23 proteins ...

  • Industries : Pathology, Medical Biotechnology
  • Countries : United States, Japan, European Union
Entyvio

Entyvio

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewEntyvio (vedolizumab; Takeda) is a monoclonal antibody approved for the treatment of Crohn’s disease. It inhibits the alpha-4-beta-7 integrin receptor, preventing the migration of T cells ...

  • Industries : Medical Biotechnology, Pathology, Therapy, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Ozanimod

Ozanimod

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewOzanimod (Celgene) is a sphingosine 1-phosphate (S1P) receptor agonist, with selectivity for the sphingosine 1-phosphate type 1 receptor (S1P1) and sphingosine 1-phosphate receptor 5 (S1P5). ...

  • Industries : Pathology
  • Countries : United States
Utibron Neohaler

Utibron Neohaler

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewNovartis, under license from Vectura and Sosei, developed Utibron, a once-daily long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination product containing indacaterol ...

  • Industries : Healthcare
  • Countries : Japan, United States, European Union
Advair

Advair

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewAdvair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). ...

  • Industries : Therapy, Chronic Disease
  • Countries : United States, Japan, European Union
Duaklir Pressair

Duaklir Pressair

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewDuaklir Pressair ([aclidinium + formoterol]; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily fixed-dose combination of the long-acting beta 2 agonist formoterol and the long-acting ...

  • Industries : Healthcare
  • Countries : United States, Japan, European Union
Filgotinib

Filgotinib

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewFilgotinib (Galapagos/Gilead) is an orally available Janus kinase (JAK)-1 inhibitor. The drug inhibits the JAK-1 receptor required for signal transduction upon binding of cytokines at the ...

  • Industries : Pathology
  • Countries : United States, Japan, European Union
Spiriva

Spiriva

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewSpiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for use in chronic obstructive pulmonary disease (COPD), and is available in a dry-powde ...

  • Industries : Chronic Disease
  • Countries : United States, Japan, European Union
Striverdi Respimat

Striverdi Respimat

  • $ 10000
  • Industry report
  • July 2018

Drug OverviewStriverdi (olodaterol; Boehringer Ingelheim) is a long-acting beta 2 agonist delivered via the Respimat inhaler. It is indicated for the once-daily maintenance treatment of airflow obstruction ...

  • Industries : Healthcare
  • Countries : United States, European Union

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on